Phase I/II Trial Results Of 131-I-Anti-B1 (Anti-CD20) Non-Myeloablative Radioimmunotherapy For Refractory B-Cell Lymphoma

The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 21 de mayo del 1996

Translation for this article does not exist

Blogs

Cancer and Hair Loss
by Bob Riter
February 11, 2016